CD300LB

Across TCGA pan-cancer cohorts, CD300LB RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of CD300LB’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CD300LB RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CD300LB is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

KIRC, LUSC, and THCA are the cancer types where CD300LB tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD300LB RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	II,III,IV	+1.300	<.001	12	view →
LUSC	Male	II,III,IV	−1.272	<.001	8	view →
THCA	Male	II,III,IV	+0.492	.001	7	view →
LUAD	All	All	−0.465	<.001	5	view →
KIRP	All	All	+0.630	<.001	2	view →
BLCA	Male	All	−0.599	.008	2	view →
ESCA	All	II,III,IV	+0.520	.015	2	view →
STAD	All	II,III,IV	+0.322	.020	2	view →
CHOL	All	All	+0.835	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

CD300LB–KIRC

Open the KIRC breakdown →